Telomere Attrition

Telomeres are repetitive TTAGGG sequences bound by protective protein complexes at chromosome ends. Each cell division erodes telomere length because standard DNA polymerase cannot fully replicate chromosome ends; telomerase, an enzyme that rebuilds telomeres, is active in stem cells and germ cells but largely silenced in most adult somatic tissue [1]. When telomeres shorten below a critical threshold, cells enter senescence or apoptosis, linking telomere attrition to the cellular senescence hallmark.

Large meta-analyses of leukocyte telomere length find a statistically significant association with all-cause mortality, but the effect size is modest: a 2018 meta-analysis reported roughly 25% higher mortality risk comparing the shortest to longest telomere length quartiles, and the association weakens substantially after adjusting for age and smoking [2]. A 2018 population-based cohort study directly compared telomere length against conventional risk predictors (age, blood pressure, cholesterol) and found telomere length added little independent predictive power for survival [3].

What the evidence does not show: no RCT has demonstrated that lengthening telomeres pharmacologically extends human lifespan or reduces disease incidence, and telomerase activation carries a theoretical cancer risk because most cancer cells reactivate telomerase to achieve unlimited division. Commercial telomere-length tests marketed directly to consumers have been criticized for poor within-person reproducibility between labs and time points, undermining their use for individual risk assessment [3].

Blueprint's biomarker panel includes cellular aging markers, but Bryan Johnson's public materials emphasize DNA methylation clocks (Speed of Aging) over telomere length as his primary aging-pace metric, reflecting the broader shift in the field away from telomere length as a stand-alone biomarker [4].

Critics, including several biogerontologists writing in response to consumer telomere testing companies, argue that telomere length varies enormously between cell types and even between chromosome arms within the same cell, so a single blood measurement is a noisy proxy at best, and that no clinical guideline currently recommends telomere length testing for individual risk stratification [3]. A broader review connecting telomere biology to lifestyle and cancer risk found that smoking, chronic stress, and obesity all associate with shorter leukocyte telomeres in observational cohorts, though as with the mortality data, these associations are modest in size and confounded by the same lifestyle factors that independently affect disease risk [5]. A separate review of telomere length and specific age-related diseases reached a similar conclusion, that the relationship is real at a population level but too noisy for individual clinical decision-making [6].

The plain takeaway: telomere attrition is a real cellular aging mechanism, but as a personal biomarker it has been largely superseded by epigenetic clocks and functional measures.